A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration

Sponsor
Genentech, Inc.
Study ID
NCT00056836
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety of this treatment.

Key Dates

First listed
Mar 26, 2003
Start date
Mar 31, 2003
Status verified
May 2014
Completion
Dec 31, 2005

Study Design

Enrollment
720 participants
Allocation
RANDOMIZED
Primary purpose
TREATMENT

Related Studies